| Not Yet Recruiting | Isavuconazole in Critically Ill Patients: Efficacy and Safety NCT07080359 | Shanghai 10th People's Hospital | — |
| Recruiting | Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study NCT05653193 | Manchester University NHS Foundation Trust | Phase 2 |
| Completed | Prospective Observational Study on the Incidence of Opportunistic Fungal Infections NCT05707156 | University of Colorado, Denver | — |
| Unknown | Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection NCT06135597 | Taipei Veterans General Hospital, Taiwan | — |
| Completed | Post Marketing Surveillance (PMS) Study of Cresemba in Korea. NCT04744454 | Pfizer | — |
| Completed | Pharmacokinetics of Voriconazole in Adult ECMO Patients NCT04868188 | University Hospitals, Leicester | — |
| Completed | Mucormycosis in COVID-19 NCT04935463 | Montefiore Medical Center | — |
| Unknown | A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection NCT04966234 | Bambino Gesù Hospital and Research Institute | Phase 2 / Phase 3 |
| Completed | COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI) NCT04818853 | University of Alabama at Birmingham | — |
| Completed | THYME AND CARVACROLL Nanoparticle Effect on Fungi NCT04431804 | Assiut University | — |
| Completed | Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients NCT05065658 | Medical University of Graz | — |
| Active Not Recruiting | Pulmonary Aspergillosis in Tuberculosis Patients NCT05045391 | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | — |
| Terminated | The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. NCT03905447 | Pulmocide Ltd | Phase 2 |
| Terminated | The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis NCT03870841 | Pulmocide Ltd | Phase 2 |
| Recruiting | PTX3-targeted Antifungal Prophylaxis NCT03828773 | Bochud Pierre-Yves | N/A |
| Completed | Invasive Pulmonary Aspergillosis and Severe Influenza NCT04232956 | University Hospital, Brest | — |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 NCT02715570 | Pulmocide Ltd | Phase 1 |
| Suspended | Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy NCT01887457 | Brynn Chappell | Phase 2 |
| Completed | Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK NCT02180165 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Can NCT02646800 | Astellas Pharma China, Inc. | Phase 4 |
| Unknown | Evaluation of Performance of An Aspergillus PCR in Tissue and Pleural Effusion Samples of Immunocompromised Pa NCT01902030 | Heidelberg University | — |
| Withdrawn | Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects NCT01188759 | Pfizer | Phase 3 |
| Withdrawn | Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis NCT01207128 | University of Arkansas | Phase 2 |
| Completed | A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus I NCT01165320 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Pre-hospital Risk Factors for Invasive Fungal Infection NCT01315925 | Catholic University of the Sacred Heart | — |
| Withdrawn | UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients NCT01622595 | University of Arkansas | — |
| Completed | An Observational Study of Fungal Biomarkers (MK-0000-089) NCT00854607 | Merck Sharp & Dohme LLC | — |
| Completed | A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administratio NCT00940017 | Pfizer | Phase 4 |
| Terminated | Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, NCT00620074 | Pfizer | Phase 4 |
| Completed | Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis NCT00531479 | Pfizer | Phase 3 |
| Completed | Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi NCT00634049 | Astellas Pharma Inc | Phase 3 |
| Completed | A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and NCT00784368 | Janssen Pharmaceutical K.K. | Phase 3 |
| Unknown | Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergil NCT01617759 | Heidelberg University | — |
| Unknown | Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT NCT00460330 | Peking University | — |
| Completed | Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis NCT00412893 | Astellas Pharma Inc | Phase 3 |
| Completed | To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment NCT00361517 | Singapore General Hospital | Phase 3 |
| Completed | Surveillance of Fungal Infections During Construction Activity NCT00473252 | Insel Gruppe AG, University Hospital Bern | — |
| Completed | Voriconazole For Chronic Bronchopulmonary Aspergillosis NCT00159822 | Pfizer | Phase 2 / Phase 3 |
| Completed | Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) NCT00082524 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection NCT00388167 | PETHEMA Foundation | — |
| Completed | A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections NCT00647907 | Pfizer | Phase 4 |
| Completed | MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0 NCT00076869 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis NCT00047827 | Astellas Pharma Inc | Phase 2 |
| Completed | A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergill NCT00037206 | Pfizer | Phase 2 / Phase 3 |
| Completed | Voriconazole to Prevent Systemic Fungal Infections in Children NCT00005912 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis NCT00263315 | Erasmus Medical Center | Phase 2 / Phase 3 |
| Completed | Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone NCT00001937 | National Cancer Institute (NCI) | Phase 3 |
| Completed | An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voricon NCT00001810 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Study of FK463 for the Treatment of Invasive Aspergillosis NCT00036166 | Astellas Pharma Inc | Phase 2 |
| Completed | Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis NCT00001646 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cy NCT00005668 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |